Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  CELLCEUTIX    CTIX

SummaryNewsCompany 
News SummaryMost relevantAll newsSector news 

Cellceutix Corp : Small Cap Stocks in Focus Today are CTIX, CWGL, FNRC and DEWM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/29/2013 | 05:50am CEST

Cellceutix (OTC: CTIX),The Crimson Wine Group (OTC: CWGL), 1st NRG Corp. (PINK: FNRC) and Dewmar International BMC, Inc. (OTC: DEWM) are our Small Cap Stocks in focus today.

Cellceutix (OTC: CTIX) is a clinical stage biopharmaceutical company developing and commercializing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its existing portfolio of clinical compounds and strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Kevetrin in the laboratory has been shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations.

For our complete article on CTIX please go here: http://tinyurl.com/otcmagic-cellceutix

The Crimson Wine Group (OTC: CWGL) owns and operates boutique, estate-based wineries that produce world class wines in the finest wine growing regions of California, Oregon and Washington. With a commitment to the preeminent appellations and vineyard sites of each region, a philosophy of hand-crafted quality and with the highest respect for the land, each CWG property produces distinct varietal wines that reflect the finest characteristics of their place of origin.

For our complete article on CWGL please go here: http://tinyurl.com/otcmagic-crimson

1st NRG Corp. (PINK: FNRC) is an exploration and production company headquartered in Denver, Colorado whose activity to date has been centered on development of the Clabaugh Ranch Field, a project developing and producing coal bed methane reserves (CBM) located in the Powder River Basin of Wyoming.

On October 21 FNRC announced a New Drilling and Production Revenues for CBM Properties in Wyoming

For our complete article on FNRC please go here: http://tinyurl.com/otcmagic-fnrc

Dewmar International BMC, Inc. (OTC: DEWM) is a U.S. based new product development, manufacturing and brand management company. Established in 2003, Dewmar's primary business strategy has been in creating high profit margins with functional foods and beverages. The Company's flagship product, Lean Slow Motion Potion, whose flavors include Yella, Purp and Easta Pink, is rated as one of the top 3 national selling relaxation beverages in the U.S. market. The company has offices in Clinton, MS; Las Vegas, NV and Houston, TX.

For our complete article on DEWM please go here: http://tinyurl.com/otcmagic-dewm

OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.

Subscribe Here: http://www.otcmagic.com/

Contact Info:

OTCMagic
info@otcmagic.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELLCEUTIX
09/16 CELLCEUTIX : Announces Appointment of Vice President for Regulatory Affairs
09/15 CELLCEUTIX CORP : Regulation FD Disclosure, Financial Statements and Exhibits (f..
09/13 CELLCEUTIX CORPORATION : Provides Business Update and Timeline of Upcoming Miles..
09/13 CELLCEUTIX CORP : Regulation FD Disclosure, Financial Statements and Exhibits (f..
09/13 CELLCEUTIX : MANAGEMENT'S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPER..
09/07 CELLCEUTIX CORPORATION : to Present at Upcoming Conferences
09/01 CELLCEUTIX CORP : MP Advisors Issues Research Report on Cellceutix Corporation
08/30 CELLCEUTIX : Further Expands Its Senior Management Team With the Addition of an ..
08/03 CELLCEUTIX : Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Mod..
07/21 CELLCEUTIX : Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Leo Ehrlich Chairman, CEO, CFO, Secretary & CAO
Arthur Peter Bertolino President & Chief Medical Officer
Krishna Kumar Menon Director & Chief Science Officer
Daniel Jorgensen Chief Medical Officer
Barry Schechter Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLCEUTIX0
AMGEN, INC.4.55%129 863
GILEAD SCIENCES, INC.-21.96%106 391
CELGENE CORPORATION-11.63%82 402
REGENERON PHARMACEUTIC..-22.80%42 552
VERTEX PHARMACEUTICALS..-29.40%21 876
More Results